American Vanguard (NYSE:AVD) executives used the company’s fourth-quarter and full-year 2025 earnings call to outline cost-reduction actions, a recently completed debt refinancing, and product development priorities as management navigates what it described as a continued downturn in the agricultural sector that began in 2023.
2025 results: sales declined, adjusted EBITDA roughly flat
For full-year 2025, CFO David Johnson said American Vanguard generated sales of $515 million, down from $547 million in the prior year, a decrease of 6%. Johnson said the result came in slightly below the company’s target range of $520 million to $535 million.
Johnson said gross profit margin improved to 29% in 2025, and operating expenses as a percentage of sales decreased slightly to 27%. He added that the company expects further improvements in both metrics in 2026 and beyond as initiatives continue.
Segment and regional demand: international weakness and mixed U.S. crop trends
Johnson said international operations sales fell 14% due to elevated channel inventories in Mexico and a persistent drought in Australia. U.S. crop sales were described as similar to the prior-year period, but management noted ongoing cautious purchasing behavior from customers.
In the Q&A session, Kaye provided additional color on fourth-quarter performance, saying revenue pressure came from both domestic and international markets. In the U.S., he cited lower Metam sales and weaker potato acreage and demand, particularly for Metam soil insecticides. He also noted a positive offset from improved herbicide sales, including Xelo.
Johnson said domestic channel stocking has “substantially abated,” with products in the ground approximately equal to sales, which he said indicates low channel inventory in the U.S. market. However, he said customers have not shown an inclination to rebuild inventory and continue purchasing on a just-in-time basis.
Outside of crop protection, Johnson said specialty sales increased 10%, driven by securing a joint development agreement, business-to-business sales, and growth in mosquito vector solutions.
Cost actions: Los Angeles facility rationalization and headquarters move
Kaye said the company decided to rationalize its Los Angeles manufacturing facility, describing it as American Vanguard’s oldest facility and “no longer competitive” in the current environment. He said the move is expected to save at least $4 million annually. As volumes shift to the company’s Axis, Alabama site, Kaye said management expects improved utilization there, which should enhance cost absorption and profitability.
In response to a question about potential proceeds from the Los Angeles changes, Kaye said the company will continue operating the site as a formulation and warehousing facility “at a much lower scale,” and there are no plans for an immediate sale. He said equipment could potentially be sold longer term, but “at the moment” the company is not planning to sell equipment.
Kaye also reiterated the previously announced plan to move the company’s global headquarters from Newport Beach to a smaller space in Irvine, California. He estimated the relocation will save approximately $0.5 million annually. Management expects both the Los Angeles facility rationalization and the headquarters move to be completed by the end of the second quarter of the current year.
When asked whether these actions were part of the company’s earlier transformation plan, Kaye said the Los Angeles and headquarters initiatives were not originally included. He characterized them as steps identified after reviewing capacity utilization and broader operating needs as the company moved from a “transformational plan” to a set of “business improvement” initiatives.
Refinancing and working capital: term loans replace revolving facility; “prepay” shift weighed on year-end debt
Management emphasized the completion of a refinancing intended to address an expiring credit facility and provide financial flexibility. Kaye said the company pursued a capital structure that would allow it to pay down the expiring facility, and the company ultimately secured two term loans—one from Centerbridge Partners and one from the existing BMO-led syndicate. He noted the new structure carries a higher average interest rate than the prior revolving credit facility but provides what he described as “a significant runway” to improve operations.
Johnson said the company selected a term loan structure that includes no equity dilution, provides stability in difficult industry conditions, and preserves the option to lower debt as results improve.
Both executives also pointed to a notable year-over-year shift in the industry’s fourth-quarter “prepay” dynamic. Kaye said the channel pulled back from prepay programs across the market due to financial strain at one competitor, contributing to higher nominal debt levels at year-end because the company historically used those collections to pay down debt. Johnson quantified the impact, saying American Vanguard collected approximately $50 million less in prepay in 2025 versus 2024, resulting in slightly increased debt at year-end.
Johnson said the company plans to reduce net working capital further and believes it can operate more efficiently as a result of supply chain leadership brought in during 2025 and the implementation of modern management techniques and software. Kaye said new software systems are expected to be fully rolled out later in the year and should help reduce inventory and raw material costs, with a stated goal of improving inventory turns to “2/4.”
Outlook: 2026 targets, new products, and long-term margin goals
For 2026, management guided to adjusted EBITDA of $44 million to $48 million on sales of $530 million to $550 million. In the Q&A, Kaye said he believes free cash flow could be positive in 2026, citing the EBITDA outlook and expected capital expenditures. Johnson said 2025 capex was about $4 million, and 2026 spending is expected to be higher but remain within a $5 million to $10 million range.
Kaye also highlighted a renewed focus on product development. He said the company has already launched one new product in 2026, Duro LQ, and expects to launch five new products in North America in total during the year, alongside additional international registrations. Kaye said American Vanguard expects to register at least 25 new products in North America by 2031. He estimated that new products in development could contribute at least $100 million in additional annual global revenue over the medium term, and said new products typically carry higher margins than the existing portfolio.
Pressed on timing, Kaye defined “midterm” as around 2030 to 2031 and said new products are defined as those less than five years from launch. He also said the company had been “in a hole” on launches after a prior organizational focus on SIMPAS technology, noting that the U.S. saw only one product launch in 2025, with an uptick expected beginning in 2027 and 2028, “mostly in 2028,” as products move through regulatory processes.
On profitability, Kaye reiterated a long-term goal of reaching a 15% EBITDA margin, saying it remains a target dependent on increasing sales and controlling costs. In the discussion, management referenced a plan assumption of 4% to 6% compound annual growth and continued efforts to improve manufacturing efficiency and reduce or better leverage operating expenses.
Finally, Kaye described the broader agricultural environment as still recovering from a downturn that began in 2023. While commodities have rebounded from lows seen in summer 2025, he said they remain below historically normal levels, farmer liquidity remains a concern, and distributors have shown little inclination to restock. He added that growers are making more last-minute crop decisions and that geopolitical issues are influencing those choices, while also pointing to “green shoots” such as farmer support payments rolling out and the potential demand impacts from higher oil prices.
About American Vanguard (NYSE:AVD)
American Vanguard Corporation (NYSE: AVD) is a developer, manufacturer and marketer of specialty chemical products for crop protection, turf and ornamental care, and public health pest control. Headquartered in Newport Beach, California, the company offers a portfolio of insecticides, herbicides, fungicides and rodenticides designed for use across agricultural, turf and urban pest management applications. Its research and development efforts focus on novel chemistries and formulation technologies that address emerging pest resistance and regulatory requirements.
The company’s product lines include emulsifiable concentrates, wettable powders, granular formulations, baits and liquid concentrates sold under proprietary brand names.
-logo-1200x675.png){kind=logo}